姜长涛教授，北京大学基础医学院长聘教授、博雅特聘教授，基础医学院副院长，博士生导师，国家杰出青年科学基金获得者、科学探索奖获得者。

所在学系：生理学与病理生理学系

研究方向：肠道微生物与代谢性疾病的发病机制研究

Email:jiangchangtao@bjmu.edu.cn

简介：

 姜长涛教授提出“代谢性疾病肠治”的新理论：首创肠道菌源宿主同工酶的新概念，发现菌源同工酶DPP4并揭示其在代谢性疾病中的重要作用（Science, 2023）；发现降解尼古丁的肠道共生菌，提出肠道共生菌通过尼古丁降解酶NicX改善代谢性疾病的新型干预策略（Nature, 2022）；揭示宿主反向调控肠道菌群代谢的新范式，发现宿主肠HIF-2α重塑菌群胆汁酸代谢酶谱，诱导代谢性疾病（Cell Metabolism, 2021）；描绘了调控代谢性疾病的肠道共生菌及其代谢物特征图谱，揭示肠道共生菌代谢物胆汁酸、尼古丁、神经酰胺及菌源宿主同工酶DPP4是介导器官间互作的关键介质，是多种代谢性疾病的共性发病机理；发现菌源DPP4、肠SMPD3、FXR、TGR5、HIF-2α等多个代谢性疾病干预的新靶标，研发出Dau-d4、解木聚糖拟杆菌、胆汁酸GUDCA与HCA、IL-22、PT2385等一系列可用于治疗代谢性疾病的生物制剂和候选药物。近5年以通讯作者在Science、Nature、Nature Medicine（3篇）、Cell Metabolism（3篇）等杂志发表SCI论文二十余篇，其中3篇入选高被引论文，1篇获F1000最高等级推荐，8篇得到国际知名学者推荐及同期评述，受邀在Nature Reviews Endocrinology, Cell Host & Microbe等期刊发表综述或述评5篇，获授权发明专利7项。获科学探索奖、中国青年科技奖、树兰医学青年奖、北美华人糖尿病学会（CADA）青年科学家奖、茅以升北京青年科技奖等奖励；主持国自然重点项目、重大研究计划及国家重点研发计划等基金，作为PI获创新研究群体项目。

“代谢性疾病肠治”新理论成果小结

代表性论文：

1) Wang K#, Zhang Z#, Hang J#, Liu J#, Guo F#, Ding Y, Li M, Nie Q, Lin J, Zhuo Y, Sun L, Luo X, Zhong Q, Ye C, Yun C, Zhang Y, Wang J, Bao R, Pang Y, Wang G*, Gonzalez FJ*, Lei X*, Qiao J*, Jiang CT*. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science. 2023 Aug 4;381(6657).

2) Chen B#, Sun L#, Zeng G#, Shen Z#, Wang K#, Yin L#, Xu F, Wang P, Ding Y, Nie Q, Wu Q, Zhang Z, Xia J, Lin J, Luo Y, Cai J, Krausz K, Zheng R, Xue Y, Zheng MH*, Li Y*, Yu C*, Gonzalez FJ*, Jiang CT*. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature. 2022 Oct;610(7932):562-568. (Commentaries and editorials from Nat Metab. 2022 Nov, Nat Rev Microbiol. 2022 Nov)

3) Wu Q#, Liang X#, Wang K#, Lin J, Wang X, Wang P, Zhang Y, Nie Q, Liu H, Zhang Z, Liu J, Pang Y, Jiang CT*. Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis. Cell Metab. 2021 Oct 5;33(10):1988-2003.

4) Sun L#, Xie C#, Wang G#, Wu Y#, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang CT*. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018 Dec;24(12):1919-1929. (Highly cited paper, data from Essential Science Indicators; Commentaries and editorials from Nat Med. 2018, Cell Metab. 2018, Nat Rev Endocrinol. 2018)

5) Zhang X#, Zhang Y#, Wang P#, Zhang SY#, Dong Y, Zeng G, Yan Y, Sun L, Wu Q, Liu H, Liu B, Kong W, Wang X, Jiang CT*. Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism. Cell Metab. 2019 Nov 5;30(5):937-951.

6) Wu Q#, Sun L#, Hu X#, Wang X, Xu F, Chen B, Liang X, Xia J, Wang P, Aibara D, Zhao S, Zeng G, Yun C, Yan Y, Zhu Y, Bustin M, Zhang SY*, Gonzalez FJ*, Jiang CT*. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J Clin Invest. 2021 May 3;131(9):e142865.

7) Zheng X#, Chen T#, Jiang R#, Zhao A#, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia WP*, Jiang CT*, Jia W*. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021 Apr 6;33(4):791-803.

8) Qi X#, Yun C#, Sun L, Xia J, Wu Q, Wang Y, Wang L, Zhang Y, Liang X, Wang L, Gonzalez FJ, Patterson AD, Liu H, Mu L, Zhou Z, Zhao Y, Li R, Liu P, Zhong C, Pang Y*, Jiang CT*, Qiao J*. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019 Aug;25(8):1225-1233. (Commentaries and editorials from Nat Med. 2019, Cell Metab. 2019, Nat Rev Drug Discov. 2019)

9) Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q, Sun D, Zhao J, Ramakrishnan SK, Sun L, Jiang C, Xue X, Tian Y, Krausz KW, Patterson AD, Shah YM, Wu Y*, Jiang CT*, Gonzalez FJ*. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308. (Commentaries and editorials from Nat Med. 2017, Nat Rev Gastroenterol Hepatol. 2017)

10) Li X#, Zhang X#, Xia J#, Zhang L, Chen B, Lian G, Yun C, Yang J, Yan Y, Wang P, Wang X, Liu B, Liu H, Liang H, Pang Y, Wang X*, Jiang CT*. Macrophage HIF-2α suppresses NLRP3 inflammasome activation and alleviates insulin resistance. Cell Rep. 2021 Aug 24;36(8):109607.

实验室成员合照